Secukinumab Vs Adalimumab for the Treatment of Ankylosing Spondilytis: A Cost Per Responder Analysis at 52 Weeks from a Moroccan Perspective

OBJECTIVES: The objective of this analysis was to estimate and compare the long-term cost per responder (CPR) based on the Assessment of Spondyloarthritis International Society (ASAS) outcomes following 52 weeks of treatment with secukinumab 150mg (SEC,anti-IL-17A) relative to adalimumab (ADA, anti-...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Value in health 2017-10, Vol.20 (9), p.A531
Hauptverfasser:	Kooli, A, Gunda, P, Toumi, J, Nikoglou, E, Jugl, SM
Format:	Artikel
Sprache:	eng
Schlagworte:	Ankylosing spondylitis Arthritis Clinical outcomes Clinical research Clinical trials Dominance Dosage Drug prices Immunotherapy Inflammatory diseases Medical treatment Money Monoclonal antibodies Patients Response rates Rheumatic diseases Spondylitis TNF inhibitors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!